Poinciana Advisors Group LLC Purchases New Position in Bristol Myers Squibb Company $BMY

Posted by Brian Himes on May 27th, 2026

Poinciana Advisors Group LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 11,229 shares of the biopharmaceutical company’s stock, valued at approximately $606,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Integrity Alliance LLC. boosted its holdings in shares of Bristol Myers Squibb by 314.0% in the fourth quarter. Integrity Alliance LLC. now owns 37,376 shares of the biopharmaceutical company’s stock valued at $2,016,000 after acquiring an additional 28,348 shares during the period. Arvest Bank Trust Division boosted its holdings in shares of Bristol Myers Squibb by 7.2% in the fourth quarter. Arvest Bank Trust Division now owns 13,053 shares of the biopharmaceutical company’s stock valued at $704,000 after acquiring an additional 875 shares during the period. Cary Street Partners Investment Advisory LLC boosted its holdings in shares of Bristol Myers Squibb by 19.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 5,582 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 901 shares during the period. Smithfield Trust Co boosted its holdings in shares of Bristol Myers Squibb by 18.4% in the fourth quarter. Smithfield Trust Co now owns 18,319 shares of the biopharmaceutical company’s stock valued at $990,000 after acquiring an additional 2,841 shares during the period. Finally, Bleakley Financial Group LLC boosted its holdings in shares of Bristol Myers Squibb by 16.4% in the fourth quarter. Bleakley Financial Group LLC now owns 33,343 shares of the biopharmaceutical company’s stock valued at $1,799,000 after acquiring an additional 4,698 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Morgan Stanley reissued an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Piper Sandler reissued an “overweight” rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Finally, UBS Group reaffirmed a “buy” rating and set a $70.00 price target on shares of Bristol Myers Squibb in a report on Friday, March 6th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $61.31.

Get Our Latest Analysis on Bristol Myers Squibb

Bristol Myers Squibb Trading Down 2.1%

NYSE:BMY opened at $58.19 on Wednesday. The stock has a fifty day moving average price of $58.46 and a two-hundred day moving average price of $56.11. The stock has a market capitalization of $118.83 billion, a price-to-earnings ratio of 16.35, a PEG ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.